Literature DB >> 16226460

Chromatin modifier enzymes, the histone code and cancer.

Helena Santos-Rosa1, Carlos Caldas.   

Abstract

In all organisms, cell proliferation is orchestrated by coordinated patterns of gene expression. Transcription results from the activity of the RNA polymerase machinery and depends on the ability of transcription activators and repressors to access chromatin at specific promoters. During the last decades, increasing evidence supports aberrant transcription regulation as contributing to the development of human cancers. In fact, transcription regulatory proteins are often identified in oncogenic chromosomal rearrangements and are overexpressed in a variety of malignancies. Most transcription regulators are large proteins, containing multiple structural and functional domains some with enzymatic activity. These activities modify the structure of the chromatin, occluding certain DNA regions and exposing others for interaction with the transcription machinery. Thus, chromatin modifiers represent an additional level of transcription regulation. In this review we focus on several families of transcription activators and repressors that catalyse histone post-translational modifications (acetylation, methylation, phosphorylation, ubiquitination and SUMOylation); and how these enzymatic activities might alter the correct cell proliferation program, leading to cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226460     DOI: 10.1016/j.ejca.2005.08.010

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  81 in total

Review 1.  The role of epigenetic regulation in stem cell and cancer biology.

Authors:  Lilian E van Vlerken; Elaine M Hurt; Robert E Hollingsworth
Journal:  J Mol Med (Berl)       Date:  2012-06-02       Impact factor: 4.599

2.  Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice.

Authors:  Takeshi Suzuki; Ken-ichi Minehata; Keiko Akagi; Nancy A Jenkins; Neal G Copeland
Journal:  EMBO J       Date:  2006-07-06       Impact factor: 11.598

3.  Method for generation of in vivo biotinylated recombinant antibodies by yeast mating.

Authors:  Nathalie Scholler; Barbara Garvik; Travis Quarles; Shaoyi Jiang; Nicole Urban
Journal:  J Immunol Methods       Date:  2006-10-30       Impact factor: 2.303

Review 4.  Chromatin, cancer and drug therapies.

Authors:  Connie C Cortez; Peter A Jones
Journal:  Mutat Res       Date:  2008-07-22       Impact factor: 2.433

5.  Epigenetic mechanisms in the pathophysiology of psychotic disorders.

Authors:  W Brad Ruzicka
Journal:  Harv Rev Psychiatry       Date:  2015 May-Jun       Impact factor: 3.732

6.  Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

Authors:  Andrei V Ougolkov; Vladimir N Bilim; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

7.  Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis.

Authors:  Joan Oliva; Fawzia Bardag-Gorce; Barbara A French; Jun Li; Laron McPhaul; Fataneh Amidi; Jeniffer Dedes; Amir Habibi; Sheila Nguyen; Samuel W French
Journal:  Exp Mol Pathol       Date:  2008-01-11       Impact factor: 3.362

Review 8.  Biophysical characterization of recombinant proteins: a key to higher structural genomics success.

Authors:  Masoud Vedadi; Cheryl H Arrowsmith; Abdellah Allali-Hassani; Guillermo Senisterra; Gregory A Wasney
Journal:  J Struct Biol       Date:  2010-05-11       Impact factor: 2.867

9.  Epigenetic regulation of cardiac muscle-specific genes in H9c2 cells by Interleukin-18 and histone deacetylase inhibitor m-carboxycinnamic acid bis-hydroxamide.

Authors:  Gipsy Majumdar; I Maria Johnson; Santosh Kale; Rajendra Raghow
Journal:  Mol Cell Biochem       Date:  2008-02-22       Impact factor: 3.396

Review 10.  Epigenetic mechanisms in mammals.

Authors:  J K Kim; M Samaranayake; S Pradhan
Journal:  Cell Mol Life Sci       Date:  2009-02       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.